BioChange

Introduction

The desire to fight aging has spawned BioChange establishment on 2017 and the development of the CellFoam™ technology for tissue regeneration and repair. We raised initial capital, a team of talented people and built a laboratory at Yokneam with a clean room for clinical production at Or Akiva.

BioChange has developed a breakthrough technology that stimulates tissue regeneration. As we age, tissues degenerate naturally or in an accelerated way, by disease or trauma. Damaged tissues lose their ability to regenerate and recover, often leading to organ loss. From aged skin and soft tissue deformations, through urinary incontinence, periodontal loss and chronic obstructive pulmonary disease, BioChange has unlocked the path to resolve unmet medical needs. 

The CellFoam™ is an injectable tissue scaffold, that mimics the natural Extra Cellular Matrix (ECM). The natural scaffold component of the tissue is what provides it with a solid physical structure. In tissues, the cells attach themselves to the structure and thrive if the structure is healthy, degenerate when the ECM is fragmented. The CellFoam™ technology is a semi-synthetic substitute made of cross-linked protein foam, capable of stimulating tissues and organs to regenerate naturally. It is bio-engineered to reboots tissue's protein production machinery. Self-cells are "persuaded" to believe they are in a healthy ECM environment, thus growing a healthy functional tissue. The CellFoam™ scaffold eventually degrades within the body into amino acids, after about 3 months of a remodeling phase, as healthy and functional tissue is formed.

The product will answer the major unmet need of collagen regeneration for soft tissue repair in general, and specifically in aesthetic dermatology and plastic surgery. 

Successful funding history and lucrative partnerships

BioChange operates a biomaterial R&D lab and manufacturing set up in Or-Akiva (25msqr ISO7 clean room), producing for the clinical phase. The company secured funding from various sources such as an R&D deal with a major strategic player, grants from IIA and SME Horizon 2020, partnership with leading institutions, e.g. the University of Milan and BEL. Also, an investment from Mr. Mauro Wjuniski, one of the leading market experts in aesthetic dermatology and serial angel investor (invested in over 30 medtech start-up and EXIT-ed several such as Alma lasers and Ventor). The company is now ready for the clinical phase and requires further funding to execute clinical studies and regulatory approvals of its leading product.  

Pipeline development strategy

CellFoam™ is our patented tissue scaffold platform technology for guided tissue regeneration. It has already achieved outstanding pre-clinical results that prove the scaffold's ability to stimulate tissue repair and recovery in various different organs.  The new tissue formed is notably healthy & lively with architecture of a young, naturally formed tissue. We aim to develop a strong organic pipeline, all based on our proprietary technology and know-how. Some of our future developments are initiated in collaboration with top-tier academia and industry partners such as University of Stanford, University of Milan and various other undisclosed biotech and pharma companies. The first product to reach the clinical phase is the Revolette™, a game changer in the field of aesthetics and plastic surgery. Other products for the treatment of urinary incontinence, for periodontal disease and for the treatment of COPD are in pre-clinical phase, after successfully completing clinical veterinary studies.

Besides the clinical products, our technology will soon be made available for the scientific research market. CellFoam™ is the optimal scaffold for bio-printing and can become the “Intel-inside” of the tissue engineering industry. 3D bioprinting techniques have shown great promise in various fields of tissue engineering and regenerative medicine. Yet, creating a tissue construct that faithfully represents the tightly regulated composition, microenvironment, and function of native tissues is still barely possible.  CellFoam™ perfectly mimics the natural tissue construct, enabling cellular adhesion and tissue growth.

The company holds one granted patent in the USA and additional two patent families in national phase. Plus one provisional patent application.

In-market product for the veterinary care

BioChange’s has already brought to market a veterinary product that solves the unmet problem of canine urinary incontinence (VetFoam™). The product offers a minimally invasive treatment option with high success rates and no adverse events. It remodels the urethra to become thicker and more functional. Readouts from a veterinary clinical study were published at the Journal of Veterinary Internal Medicine in mid 2020. A newer product is soon finishing clinical phase with already promising results in treating periodontal disease, the largest unsolved need in pet-care.

The pet-care market is booming in recent years, as companion pet become like family members. VetFoam™ offer new innovative products pipeline to our companion animal patients. By doing so we achieve two important goals: helping animals who suffer from diseases, sometimes with unmet needs, and providing more validation to the platform technology. In addition, these products provide the company with cash flow, while reducing the amount of capital raised on our way to achieving our clinical goals.